Neisseria Meningitidis

Epidemiology

  • xxx

Microbiology

  • Member of Neisseria Genus (see Neisseria, [[Neisseria]])

Diagnosis

  • Blood Cultures:
  • Lumbar Puncture (LP):
  • Brain MRI:

Clinical Manifesttaions


Treatment

Vaccination

  • Bexsero (Novartis): approved for use in Europe and Australia in January 2013
    • This is the only vaccine in production that protects against Neisseria meningitidis serogroup B (MenB)

Antibiotics

  • xxx

References

  • Food and Drug Administration, HHS. Charging for investigational drugs under an investigational new drug application. Final rule. Fed Regist. 2009;74:40871-900 [MEDLINE]
  • Food and Drug Administration, HHS. Charging for investigational drugs under an investigational new drug application. Final rule. Fed Regist. 2009;74:40871-900 [MEDLINE]
  • Food and Drug Administration, HHS. Expanded access to investigational drugs for treatment use. Final rule. Fed Regist. 2009;74:40900-45 [MEDLINE]
  • Meningococcal antigen typing system (MATS) based coverage prediction for the 4CMenB vaccine in United States. In: Frosch M, Rudel T, Vogel U, eds. XVIIIth International Pathogenic Neisserial Conference. Wurzburg, Germany; 2012
  • Bexsero: a multicomponent vaccine for prevention of meningococcal disease. Hum Vaccin Immunother. 2012;8:174-83 [MEDLINE]
  • The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine. 2012;30 Suppl 2:B87-97. [PMID: 22607904]
  • Commentary: European Medicines Agency recommends approval of a broadly protective vaccine against serogroup B meningococcal disease. Pediatr Infect Dis J. 2013;32:372-3 [MEDLINE]